- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01849536
Corneal Biomechanics and Continuous IOP Monitoring Using Soft Contact Lenses in Glaucomatous Patients (BIOLENS)
Ocular hypertension and its fluctuations is a major risk factor of glaucoma onset and progression. In normal eyes, IOP presents a circadian rhythm, but in glaucomatous eyes IOP circadian rhythm is altered and varied widely between patients. To date, the only way to evaluate 24 hour IOP fluctuations is a regular GAT-IOP measurement during a 24-hour hospitalization. This method is expensive and does not reflect physiological conditions because it requires IOP measurements during sleeping periods that may potentially produce artifacts.
Sensimed AG has developed a new medical device SENSIMED Triggerfish® that enables a 24-hour continuous monitoring of IOP fluctuations. As any IOP measurements methods, this medical device might be influenced by corneal properties of the cornea as central corneal thickness, keratometry or biomechanics. We, therefore, investigate the corneal lens tolerance, potential modifications of corneal parameters after a 24-hour wear of the lens, and its influence on data collected during the whole period of analysis. Then we will also analyze the influence of corneal parameters on continuous IOP fluctuations measured with the contact sensor and finally the correlation between data collected and the rate of progression (severity) of glaucoma evaluated with visual field test or optic nerve head damages.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Bordeaux
-
CHU de Bordeaux, Bordeaux, France, 33000
- Service d'ophtalmologie Hôpital Pellegrin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 40 year-old
- Signed informed consent
Visual field defect : at least 2 visual field already done, only the second one is considered for the visual field defect diagnosis, using theses criterion:
- 3 adjacent points with at least 5db loss
- Or 1 point with at least 10 db loss
- Or a 10db difference between two adjacent points on either sides of the nasal horizontal meridian
- Open angle glaucoma patients with a progressive visual field
- For women of childbearing potential, adequate contraception
Exclusion Criteria:
- Corneal dystrophy, scars or corneal surgery
- Iridocorneal angle opening less than 3 using Shaeffer classification
- History of glaucoma surgery
- Any contraindications with the SENSIMED Triggerfish® device, as written in the user manual (active eye disease, severe dry eye, contraindications for silicone contact lens wear…)
- Diabetes
- Sleep Apnea Syndromes
- Cataract surgery
- High myopia
- Pregnancy and lactation
- Patients not able to understand the character and individual consequences of the investigation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SENSIMED Triggerfish®
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Corneal biomechanics influence on IOP fluctuation.
Time Frame: 24h
|
To evaluate corneal biomechanics influence on IOP fluctuation using SENSIMED Triggerfish® for glaucoma patients with a progressive visual field.
|
24h
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between visual field defects and IOP fluctuations measurements.
Time Frame: 24h
|
To evaluate the correlation between visual field defects and IOP fluctuations measurements.
|
24h
|
Correlation between the severity of optic nerve head damages and IOP. fluctuations measurements
Time Frame: 24h
|
To evaluate the correlation between the severity of optic nerve head damages measured with OCT and IOP fluctuations measurements.
|
24h
|
Lens tolerance and corneal parameters after 24-hours of contact lens wear.
Time Frame: 24h
|
To evaluate lens tolerance and corneal parameters after 24-hours of contact lens wear (Pachymetry, Corneal hysteresis and Keratometry ).
|
24h
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cédric SCHWEITZER, MD, University Hospital Bordeaux, France
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2012/20
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Open Angle Glaucoma With a Progressive Visual Field
-
Centre Hospitalier Universitaire, AmiensRecruitingOpen-angle Glaucoma | Visual FieldFrance
-
Columbia UniversityCompletedGlaucoma, Open-Angle | Visual Field Defect, PeripheralUnited States
-
Glaukos CorporationCompletedSubjects With Primary Open-angle Glaucoma (POAG)Armenia
-
Glaukos CorporationCompletedSubject With Primary Open-angle Glaucoma (POAG)Armenia
-
Glaukos CorporationCompletedSubjects With Primary Open-angle Glaucoma (POAG)Armenia
-
Maisonneuve-Rosemont HospitalRecruitingPatients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)Canada
-
Chittagong Medical CollegeCompletedTo See the Safety and Efficacy of the Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma PatientsBangladesh
Clinical Trials on SENSIMED Triggerfish®
-
Sensimed AGTerminatedPrimary Open-angle Glaucoma (POAG) PatientUnited States
-
Sensimed AGCompletedSleep Apnea, Obstructive | Primary Open-angle GlaucomaUnited States
-
Sensimed AGClinique MonchoisiTerminatedPrimary Open Angle GlaucomaSwitzerland
-
Sensimed AGCompleted
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Normal Tension GlaucomaPoland
-
Sensimed AGWithdrawn
-
Sensimed AGTerminatedHealthy SubjectsSwitzerland
-
Sensimed AGUniversity Hospital, GenevaTerminated